end
nascent
eukaryot
messeng
rna
mrna
cotranscript
modifi
addit
cap
structur
structur
consist
guanosin
link
triphosph
bridg
rna
end
figur
cap
structur
methyl
nitrogen
posit
g
structur
gpppn
metazoan
often
convert
structur
omethyl
first
n
ribos
structur
gpppn
mrna
structur
play
sever
key
biolog
function
review
ref
cap
increas
mrna
stabil
protect
mrna
exoribonucleas
ii
particip
premrna
splice
export
cytoplasm
iii
ensur
recruit
mrna
ribosom
recogn
eukaryot
translat
initi
factor
iv
initi
translat
mrna
protein
addit
demonstr
cap
structur
marker
self
prevent
detect
mechan
cellular
innat
immun
first
report
host
cell
sensor
toll
like
receptor
tlr
retino
acidinduc
gene
rig
like
receptor
could
detect
uncap
rna
triphosph
end
recent
also
shown
rigi
melanoma
differentiationassoci
protein
recogn
miscap
rna
lack
omethyl
first
transcrib
nucleotid
initi
signal
cascad
lead
express
releas
cytokin
type
interferon
turn
interferon
induc
antivir
state
neighbor
cell
among
interferonstimul
gene
isg
interferoninduc
protein
tetratricopeptid
repeat
ifit
recogn
miscap
rna
inhibit
translat
within
host
cell
eukaryot
mrna
gener
cap
canon
rna
cap
pathway
gener
requir
four
sequenti
reaction
elucid
four
decad
ago
catalyz
rna
triphosphatas
rtpase
guanylyltransferas
gtase
guanin
methyltransferas
omtas
respect
figur
contrast
mani
virus
evolv
mrna
cap
machineri
order
expedit
effici
viral
protein
product
escap
innat
immun
detect
remark
pathway
viral
mrna
cap
highli
divers
almost
converg
rna
cap
structur
common
viral
cellular
mrna
figur
virus
express
set
cap
enzym
four
type
rna
cap
pathway
evidenc
far
first
one
virus
use
cap
pathway
similar
observ
eukaryot
cell
figur
phosphat
end
nascent
viral
hydrolyz
rtpase
activ
held
rtpase
helicas
domain
concomitantli
gtp
recruit
gtpase
often
form
coval
adduct
lysgmp
transfer
gmp
onto
rna
diphosph
end
occur
dna
virus
eg
poxvirus
mimiviru
baculovirus
well
supposedli
sever
posit
strand
rna
virus
eg
flaviviru
coronaviru
cap
cap
methyl
posit
either
one
bifunct
omtas
eg
flavivirus
two
separ
enzym
eg
coronavirus
nonseg
neg
strand
nn
virus
use
distinct
rna
cap
pathway
figur
studi
nn
vsv
code
larg
l
protein
perform
replicationtranscript
cap
viral
rna
cap
synthesi
ensur
polyribonucleotidyltransferas
prntase
form
coval
link
conserv
histidin
nascent
viral
mrna
presenc
gdp
cap
structur
form
mtase
domain
c
terminu
l
protein
methyl
cap
structur
ribos
posit
first
transcrib
nucleotid
follow
capguanin
posit
togavirida
also
synthes
cap
structur
use
nonconvent
mechan
figur
viru
famili
also
bamboo
mosaic
viru
plant
pathogen
relat
potexviru
genu
code
enzym
alphaviru
methyl
gtp
form
coval
gmp
complex
last
four
pathway
virus
arenavirida
bunyavirida
orthomyxovirida
famili
use
cap
snatch
strategi
steal
cap
structur
cellular
mrna
figur
purpos
capbind
domain
polymeras
n
protein
first
recogn
methyl
host
mrna
orthomyxovirida
bunyavirida
cellular
mrna
cleav
nucleotid
downstream
cap
structur
viral
endonucleas
snatch
rna
shorter
nucleotid
arenavirida
endonucleas
shortcap
rna
subsequ
use
primer
viral
mrna
synthesi
viral
polymeras
use
strategi
virus
kill
two
bird
one
stone
decap
cellular
mrna
block
express
cellular
rna
favor
express
viral
rna
nascent
viral
rna
emerg
viral
replicasetranscriptas
ppprna
process
pprna
decor
guanin
cap
five
type
viral
rna
triphosphatas
involv
first
step
canon
viral
rna
cap
pathway
metazoan
metalindepend
rtpase
baculoviru
bvp
constitut
first
type
enzym
belong
cysteinylphosphatas
famili
whose
fold
catalyt
mechan
larg
number
cellular
counterpart
thu
limit
interest
drug
design
target
sake
select
second
type
hydrolysi
rna
gphosphat
achiev
genuin
metaldepend
dedic
viral
tpase
case
plant
fungi
protozoan
dna
virus
mimiviru
poxvirus
baculovirus
distinct
tpase
socal
triphosph
tunnel
metalloenzym
ttm
superfamili
metaldepend
activesit
lie
bottom
tunnel
shape
seem
wellsuit
accommod
specif
inhibitor
exhibit
bind
affin
nanomolar
rang
third
fourth
type
reovirida
also
genuin
rtpase
hitlik
famili
rotaviru
octam
socal
rna
cap
assembl
line
larg
enzym
complex
encompass
bluetongu
mammalian
orthoreoviru
respect
rna
cap
assembl
line
repres
model
conceal
nascent
viral
rna
compact
chemic
reaction
sequenc
last
fifth
type
hydrolysi
rna
gphosphat
achiev
engin
viral
helicas
whose
ntpase
activ
site
also
abl
accommod
ppprna
ntpase
activ
site
incorpor
deadh
sequenc
walker
b
motif
respons
fuel
helicas
movement
along
rna
inhibitor
site
therefor
bifunct
kill
helicas
rtpasecap
activ
howev
probabl
due
highli
dynam
natur
helicas
enzym
potent
inhibitor
report
far
viral
rna
cap
pathway
gtase
amongst
first
enzym
identifi
nearli
forti
year
ago
form
easili
detect
gmpenzym
adduct
biochem
structur
character
reveal
gtase
belong
atpdepend
dna
ligas
famili
howev
viru
famili
dsdna
virus
reovirida
reli
pure
gtase
includ
cap
pathway
rtpase
rna
capmtas
gmp
load
onto
enh
catalyt
lysin
part
kxdg
il
motif
form
typic
coval
adduct
later
transfer
viral
diphosph
rna
detail
mechan
infer
eleg
crystallograph
mechanist
studi
gtase
inhibitor
isol
yet
figur
mechanist
data
might
serv
guid
design
activesit
inhibitor
provid
select
achiev
amongst
larg
number
cellular
gmptransfer
enzym
remark
mani
rna
virus
use
variat
pingpong
mechan
gmp
transfer
eg
see
nn
virus
togavirida
detail
guaninecap
acquisit
also
remain
elus
larg
flaviviru
genu
well
whole
nidoviral
order
coronavirida
arterivirida
flavivirus
put
coval
gmpmtase
domain
adduct
propos
sinc
put
catalyt
lysin
conserv
coval
adduct
remain
question
flavivirus
perhap
nidoviral
may
well
specif
rna
sequenc
requir
express
essenti
element
catalyz
cap
addit
without
coval
intermedi
methyl
cap
involv
two
activ
transfer
methyl
group
cap
guanosin
residu
rna
omtas
methyl
ribos
residu
cap
structur
despit
highli
diverg
sequenc
mtase
harbor
canon
rossman
fold
sadenosyl
methionin
sam
methyl
donor
bind
pocket
rnaandor
capbind
site
catalyt
site
sam
usual
maintain
close
proxim
catalyt
site
conserv
dxg
motif
mtase
shown
harbor
conserv
kdke
catalyt
tetrad
particip
substrat
posit
inlin
methyl
transfer
reaction
methyl
sulfur
atom
sam
serv
electrophil
undergo
attack
activ
oxygen
rna
substrat
sam
convert
sadenosyllhomocystein
sah
process
contrast
mechan
remain
elus
catalysi
involv
tetrad
residu
easili
identifi
protein
sequenc
viru
famili
code
two
differ
mtase
domain
carri
capbind
site
eg
poxvirus
coronavirus
structur
inhibitor
target
enzym
involv
viral
rna
cap
pathway
inhibitor
block
gtase
activ
report
ribavirin
triphosph
first
propos
target
gtase
activ
cap
enzym
screen
effort
identifi
thioxothiazolidin
madtp
deriv
potent
inhibitor
flavivirus
chikungunya
viru
gtase
sever
mtase
inhibitor
report
ribavirin
triphosph
report
gtase
panel
samsah
analogu
sinefungin
inhibitor
sever
viral
mtase
vitro
sah
analogu
deriv
compound
also
inhibit
specif
flavivir
mtase
nonnucleosid
inhibitor
obtain
fragmentbas
drugdesign
approach
target
flavivir
mtase
dengu
zika
viru
also
report
recent
virtual
screen
also
use
identifi
dengu
mtase
inhibitor
nsc
seri
zika
viru
compound
regul
sahsam
balanc
show
potent
broadspectrum
antivir
activ
includ
ebola
viru
see
text
antivir
effect
supposedli
link
inhibit
mtase
increas
sah
pool
chemic
structur
repres
endon
inhibitor
shown
crystal
within
activ
site
influenza
viru
pa
enzym
cap
analogu
exemplifi
gtp
sever
inhibitor
capbind
protein
identifi
xray
structur
analysi
influenza
viru
complex
correspond
ligand
direct
bind
could
demonstr
correspond
highli
potent
influenza
inhibitor
methyl
limit
viral
rna
detect
riglik
sensor
mtase
bear
potenti
new
antivir
target
first
class
inhibitor
consist
sammimet
act
competitor
mtase
cosubstr
wherea
viral
mtase
inhibit
sam
analogu
sinefungin
like
specif
inhibitor
discov
upon
structureact
relationship
analysi
figur
accordingli
sam
mimet
accommod
specif
uniqu
hydrophob
pocket
adjac
sambind
site
flaviviru
mtase
inhibit
dengu
viru
replic
addit
dock
experi
indic
compound
might
bind
highli
homolog
mtase
zika
viru
zikv
second
possibl
develop
specif
inhibitor
illustr
fragmentbas
drug
design
approach
use
approach
alloster
inhibitor
target
denv
zikv
mtase
vitro
recent
report
median
inhibitori
activ
remain
mm
rang
addit
use
virtual
screen
approach
ten
potenti
inhibitor
zikv
mtase
sort
compound
even
compound
yet
demonstr
limit
mtase
activ
vitro
show
antivir
activ
zikvinfect
cell
ec
rang
mm
thu
like
molecular
dock
use
target
conserv
druggabl
site
designspecif
mtase
inhibitor
third
possibl
emerg
mtase
activ
protein
partner
eg
coronavirus
peptidomimet
report
specif
inhibitor
final
also
possibl
downregul
mtase
activ
level
modul
intracellular
samsah
balanc
use
sah
hydrolas
inhibitor
strategi
success
use
inhibit
ebola
viru
replic
mice
although
latter
inhibitor
might
also
effect
interferon
product
alphavirus
evolv
bifunct
mtasegtas
embed
protein
synthet
structur
contrast
viral
mtase
use
gtp
rather
cap
structur
substrat
gtp
thu
first
methyl
posit
gtp
gtp
form
coval
link
catalyt
histidin
releas
inorgan
pyrophosph
figur
methyl
gmp
subsequ
transfer
onto
nascent
viral
rna
yield
structur
although
structur
data
yet
avail
uniqu
unconvent
cap
reaction
make
attract
target
antivir
drug
design
recent
small
molecul
inhibitor
alphaviru
report
block
chikv
replic
mm
rang
mm
figur
select
resist
virus
demonstr
guanylyltransferas
activ
target
enzym
perform
rna
addit
mechanist
variat
classic
rtpasegtas
pathway
wherea
gtase
bind
gmp
coval
accept
diphosph
rna
prntase
bind
monophosph
rna
accept
gdp
figur
pathway
lead
end
product
rna
one
could
think
chemistri
underli
coval
attach
gmp
prna
would
relat
sinc
gtp
triphosph
rna
structur
relat
receiv
nucleophil
attack
aphosph
howev
gtase
bind
gmp
elysilphosphoramid
intermedi
wherea
prntase
bind
monophosph
rna
n
histidin
intermedi
furthermor
protein
fold
gtase
prntase
show
obviou
homolog
suggest
coval
attach
promot
pingpong
mechan
invent
twice
evolut
drug
design
point
view
gtase
might
difficult
inhibit
high
select
inde
belong
larg
famili
dna
ligas
whose
structur
activ
larg
repres
mammalian
world
prntase
uniqu
repres
nn
virus
activ
demonstr
rhabdovirida
far
prntaselik
domain
identifi
mani
nn
viru
famili
paramyxovirida
pneumovirida
filovirida
name
famili
signific
medic
interest
recent
progress
structur
determin
enzym
atom
resolut
greatli
stimul
drug
design
near
futur
three
viral
famili
orthomyxovirida
arenavirida
bunyavirida
carri
capbind
domain
rna
endonucleas
domain
replicas
complex
see
whether
latter
domain
fuse
polymeras
core
carri
separ
subunit
fold
mechan
action
endonucleas
suggest
common
phylogenet
origin
endonucleas
belong
pddexk
superfamili
cationdepend
nucleas
lysin
main
catalyt
residu
acid
de
residu
coordin
two
metal
ion
togeth
histidin
residu
conserv
orthomyxovirida
bunyavirida
enzym
replac
third
acid
residu
arenavirida
endonucleas
share
common
twometalion
mechan
distinct
metal
prefer
though
featur
exploit
drug
design
activ
site
environ
show
virusspecif
structur
variat
metal
chelat
shown
druggabl
raltegravir
relat
pharmacophor
case
inhibit
hiv
integras
inde
possibl
chelat
metal
enzym
activ
site
obtain
target
specif
occup
uniqu
activ
site
environ
henc
metal
chelat
acid
dpba
act
bunyaviru
orthomyxoviru
endonucleas
inhibitor
may
provid
pharmacophor
motif
design
potent
compound
capbind
domain
also
attract
antivir
target
figur
xray
structur
influenza
b
viru
complex
gtp
reveal
conserv
caprecognit
mechan
methyl
guanosin
stack
two
aromat
residu
similar
bind
mode
eukaryot
initi
factor
howev
fold
uniqu
compar
capbind
protein
rais
possibl
identifi
specif
inhibitor
cap
analogu
pharmacophor
first
demonstr
select
inhibit
capbind
effect
recent
anoth
capbind
domain
blocker
influenza
viru
identifi
compound
show
robust
antivir
activ
phase
trial
demonstr
valid
antivir
target
biochem
principl
inhibitor
interfer
viral
rna
cap
rna
cap
reaction
involv
number
differ
enzym
rna
substrat
order
make
bona
fide
rna
cap
effici
inhibitor
depend
biochem
properti
embed
chemic
structur
abil
access
replic
site
bind
viral
target
interfer
catalyt
step
imped
enzymat
conform
chang
figur
report
main
inhibitor
shown
antirna
cap
properti
number
differ
bind
site
rna
cap
enzym
accommod
substrat
repres
natur
target
inhibitor
substrat
exhibit
wide
chemic
divers
small
organ
molecul
exampl
sadenosyl
methionin
larg
polar
substrat
exampl
rna
aim
competit
inhibitor
displac
substrat
take
account
mainli
two
factor
substrat
bind
energi
bind
surfac
strength
bond
could
high
case
larg
rna
bind
groov
actual
intracellular
concentr
natur
compet
substrat
case
gtp
put
competit
inhibitor
would
reach
high
intracellular
concentr
andor
exhibit
high
affin
displac
millimolar
concentr
natur
nucleotid
analogu
compet
sam
sah
cellular
concentr
latter
order
magnitud
lower
inhibit
depend
substrat
bind
affin
also
effici
follow
catalyt
reaction
exampl
ribavirin
tp
rna
cap
inhibitor
make
ribavirin
mp
coval
adduct
gtase
inhibit
effici
depend
thu
tightli
ribavirin
triphosph
bind
also
fast
react
coval
link
thu
given
ratio
catalyt
constant
k
cat
divid
affin
constant
k
detail
kinet
constant
obtain
use
presteadi
state
kinet
still
lack
describ
precis
differ
rna
cap
pathway
possibl
mechan
action
rna
cap
inhibitor
eg
direct
action
intracellular
pool
rna
cap
substrat
exemplifi
ribavirin
whose
mechan
action
clearli
pleiotrop
whose
metabolit
ribavirin
monophosph
known
inhibit
cellular
imp
dehydrogenas
enzym
result
profound
deplet
intracellular
gtp
pool
deplet
pleiotrop
effect
stand
inhibit
gtase
reaction
anoth
exampl
inhibitor
cellular
sah
hydrolas
latter
enzym
maintain
low
level
sah
potent
reactionproduct
inhibitor
rna
capmtas
structur
data
larg
replicasetranscriptas
complex
nn
virus
orthomyxovirida
bunyavirida
emerg
recent
shown
replicasetranscriptas
complex
perform
rna
synthesi
cap
concert
manner
rna
substrat
travel
sever
protein
domain
thu
like
alloster
inhibitor
found
act
sand
machin
alter
fine
tune
conform
chang
structur
rearrang
need
expedit
rna
cap
event
also
possibl
proteinprotein
interfac
target
choic
near
futur
design
entir
novel
class
antivir
sam
use
methyl
donor
mani
cellular
mtase
like
develop
alloster
proteinprotein
interact
inhibitor
may
superior
sam
mimet
sah
hydrolas
inhibitor
term
select
design
toward
uniqu
site
viral
enzym
viral
rna
cap
take
place
genom
replic
event
rna
virus
eg
flavivirus
much
higher
occurr
sever
viral
mrna
gener
replic
genom
eg
nn
virus
nidoviral
signific
rna
cap
antivir
target
could
legitim
question
instanc
exampl
rna
cap
rare
event
viru
life
cycl
howev
past
research
decad
contrario
unveil
rna
cap
essenti
viru
replic
fact
interest
target
design
potent
antivir
due
two
main
reason
incompleteinhibit
rna
cap
trigger
potent
host
immun
respons
ad
direct
inhibit
viral
gene
express
ii
structur
function
studi
viral
cap
enzym
reveal
profound
uniqu
viral
enzym
involv
show
promis
achiev
high
drug
select
thu
littl
doubt
high
resolut
structur
coupl
detail
enzym
mechan
inspir
design
highli
potent
directact
antivir
near
futur
